or Try an Advanced Search...

    Technical Analysis for CRVS - Corvus Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    A 9.10 2.94% 0.26
    CRVS closed up 2.94 percent on Friday, November 1, 2024, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    Earnings due: Nov 5
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Very Strong Up Up Up
    Historical CRVS trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing High Bullish 0.00%
    NR7 Range Contraction 0.00%
    New 52 Week High Strength 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    Wide Bands Range Expansion 2.94%
    Overbought Stochastic Strength 2.94%
    Spinning Top Other 3.41%
    New 52 Week High Strength 3.41%
    Wide Bands Range Expansion 3.41%
    Older End-of-Day Signals for CRVS ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 19 hours ago
    60 Minute Opening Range Breakout about 21 hours ago
    Rose Above Previous Day's High about 23 hours ago
    New 52 Week High about 23 hours ago
    Up 3% about 23 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    CRVS Chart by TradingView
    Basic chart:

    Profile

    Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that plan to initiate a Phase 1/1b clinical trial for adenosine, an immune checkpoint. The company also develops a product candidate, an anti-CD73 monoclonal antibody that inhibits the production of adenosine. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Life Sciences Immunology Immune System Cancer Immunotherapy Monoclonal Antibody Cancer Cell Immune Checkpoint Adenosine Oncology Therapies Cd73

    Is CRVS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 22 Corvus stock climbs 7% following Mizuho upgrade
    Oct 17 Insiders of Corvus Pharmaceuticals Getting Good Value On Their US$1.03m Investment
    Sep 30 Why Nio Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
    Sep 18 Casella Waste Systems, SES AI And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
    Sep 11 Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug
    Sep 10 Corvus spikes as late-stage trial for lead asset announced
    Sep 10 Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
    Sep 3 Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    Sep 3 Corvus Pharmaceuticals Eyes Phase 3 Trials: Soquelitinib's Promise In PTCL
    Sep 2 Corvus Pharmaceuticals: Soquelitinib's High Stakes In PTCL Therapy
    See more CRVS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 9.28
    52 Week Low 1.23
    Average Volume 615,111
    200-Day Moving Average 3.09
    50-Day Moving Average 5.88
    20-Day Moving Average 7.40
    10-Day Moving Average 8.31
    Average True Range 0.58
    RSI (14) 82.17
    ADX 53.62
    +DI 34.64
    -DI 8.42
    Chandelier Exit (Long, 3 ATRs) 7.55
    Chandelier Exit (Short, 3 ATRs) 6.93
    Upper Bollinger Bands 9.59
    Lower Bollinger Band 5.22
    Percent B (%b) 0.89
    BandWidth 59.01
    MACD Line 0.93
    MACD Signal Line 0.82
    MACD Histogram 0.1143
    Fundamentals Value
    Market Cap 446.25 Million
    Num Shares 49 Million
    EPS -0.64
    Price-to-Earnings (P/E) Ratio -14.22
    Price-to-Sales 0.00
    Price-to-Book 2.44
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 9.79
    Resistance 3 (R3) 9.77 9.53 9.68
    Resistance 2 (R2) 9.53 9.35 9.54 9.64
    Resistance 1 (R1) 9.31 9.24 9.42 9.33 9.60
    Pivot Point 9.07 9.07 9.12 9.08 9.07
    Support 1 (S1) 8.85 8.89 8.96 8.87 8.60
    Support 2 (S2) 8.61 8.78 8.62 8.56
    Support 3 (S3) 8.39 8.61 8.53
    Support 4 (S4) 8.41